Chemical Nameivosidenib
Dosage FormTablet (oral; 250 mg)
Drug ClassInhibitors
CompanyAgios Pharmaceuticals Inc.
Approval Year2018


  • To treat acute myeloid leukemia with a susceptible IDH1 mutation.
  • To treat relapsed or refractory acute myeloid leukemia in adults.
  • To treat novel acute myeloid leukemia in adults who are ≥ 75 years of age or who are not eligible for the use of intensive induction chemotherapy.
Last updated on 10/14/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tibsovo (Ivosidenib) Prescribing Information 2018Agios Pharmaceuticals Inc., Cambridge, MA
Document TitleYearSource
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.2018The New England Journal of Medicine